
Nextcure (NXTC) Stock Forecast & Price Target
Nextcure (NXTC) Analyst Ratings
Bulls say
NextCure Inc. has secured global rights to SIM0505, which could generate up to $745 million in upfront and milestone payments, alongside tiered royalties that may reach double-digit percentages on net sales, indicating strong potential revenue streams. The company is focused on adding value to its ADC programs while acknowledging the need to adjust valuations for NC410 and NC525, with a long-term outlook extending to mid-2026. Additionally, preclinical data for SIM0505 exhibits promising anti-tumor activity and a favorable safety profile, supporting the company's continued advancement in clinical trials, including a planned Phase I study in the U.S.
Bears say
NextCure Inc. has recently revised its projected enterprise value, decreasing it significantly from $75 million to $37.5 million, which reflects a concerning outlook for the company’s financial health. The substantial drop in the price target from $36 to $15 suggests a lack of confidence in achieving future milestones, particularly given the risks associated with the clinical success of its therapies. Additionally, the company is seeking partnerships for several programs, indicating potential limitations in its financial resources and ability to independently advance its drug candidates.
This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.
Nextcure (NXTC) Analyst Forecast & Price Prediction
Start investing in Nextcure (NXTC)
Order type
Buy in
Order amount
Est. shares
0 shares